Sacituzumab tirumotecan Phase 2 anal/rectal cancer trial

ClinicalTrials.gov published registration details for NCT07511023, a Phase 2 clinical trial investigating sacituzumab tirumotecan (a Trop-2 directed antibody-drug conjugate) in patients with anal or rectal cancer. The study appears to be a single-arm trial for participants with metastatic or locally advanced disease who have received prior systemic therapy.

Clinical investigators and research sites should ensure the trial is listed on their internal tracking systems if actively recruiting. Patients seeking enrollment should contact the listed recruiting sites. No compliance deadline or reporting obligation is imposed by this registration notice—this is an informational filing for public transparency under NIH requirements for clinical trial registration.